Search

Carcinogenic transformation of a cell requires bypassing senescence and becoming immortalized. A cellular senescence-like phenotype can be induced in immortal Li-Fraumeni syndrome (LFS) cells by treating them with the DNA methyltransferase inhibitor 5-aza-deoxycytidine. Our microarray-based expression profiling studies of spontaneously immortalized LFS cell lines identified genes that may provide the growth advantage required for the cells to become immortal. Several members of the IGFBP superfamily of genes fit the profile of genes involved in immortalization: silenced during immortalization and reactivated by 5-aza-deoxycytidine. Overexpression of IGFBP3 or IGFBPrP1 in the immortal LFS cell lines suppressed cell growth and inhibited colony formation. Both genes have the expression pattern of an epigenetically regulated gene and contain CpG islands suitable for methylation-dependent silencing. Analysis of how IGFBPs regulate immortalization will lead to a better understanding of this process and may lead to novel methods for the prevention and treatment of cancer.

The insulin-like growth factor (IGF) family plays an important role in follicle development, dominant follicle growth and steroidogenesis, and follicular atresia. Insulin-like growth factor (IGF)-II is the primary IGF in human ovary, acting as a mediator of gonadotropin action. IGF-II stimulates granulosa steroidogenesis, and its actions, along with those of follicle-stimulating hormone (FSH), are inhibited by IGF binding protein (IGFBP)-4. At the time of follicle selection, in the estrogen-dominant follicle, granulosa IGF-II synthesis increases dramatically. Simultaneously, in the selected follicle, IGFBP-4, an inhibitor of IGF-II action and abundant within androgen-dominant follicles, is proteolyzed by a specific IGFBP-4 protease, resulting in decreased affinity of IGFBP-4 for IGF-II. The IGFBP-4 protease has recently been identified in human ovary as pregnancy-associated plasma protein-A (PAPP-A). In the Graafian follicle, IGF-II bioavailability is increased to act as a mediator of FSH action, by increased synthesis of this peptide and concomitant decrease in an inhibitor of its actions by proteolysis of IGFBP-4.

Over the past few years, there has been an explosion of data in the scientific literature regarding the various components of the IGF axis. IGFBPs and related molecules are now believed to be critical elements in numerous cellular processes and key factors in several disease states related to abnormal tissue and somatic growth. Recently, the BP-Prs were included in this complex system, and their importance is being unraveled. The upcoming years will undoubtedly bring even more information on the molecular biology of these key cellular regulators. These discoveries are likely to lead to better understanding of growth and cellular regulation and to development of novel therapeutic approaches to a variety of diseases.